Stephen Farber - Mednax Chief Financial Officer, Executive Vice President
| MD Stock | USD 14.47 0.32 2.26% |
President
Mr. Stephen D. Farber is Chief Financial Officer, Executive Vice President of the Company, Prior to joining the Company, Mr. Farber served as Executive Vice President and Chief Financial Officer of Kindred Healthcare, Inc. from February 2014 until its sale in July 2018. From May 2013 to December 2013, Mr. Farber served as Executive Vice President, Chief Restructuring Officer and Chief Financial Officer of RuralMetro Corporationrationration. Prior to joining RuralMetro Corporationrationration, Mr. Farbers principal roles included serving from 2011 to 2012 as ExecutiveinResidence with Warburg Pincus LLC, a global private equity firm, from 2006 to 2009 as Chairman and Chief Executive Officer of Connance, Inc., a predictive analytics provider to healthcare companies, and from 2002 to 2005 as Chief Financial Officer of Tenet Healthcare Corporationrationration. since 2018.
| Age | 49 |
| Tenure | 6 years |
| Address | 1301 Concord Terrace, Sunrise, FL, United States, 33323 |
| Phone | 954 384 0175 |
| Web | https://www.pediatrix.com |
Mednax Management Efficiency
The company has Return on Asset (ROA) of 0.0467 % which means that for every $100 of assets, it generated a profit of $0.0467. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.2986) %, which implies that it produced no returns to current stockholders. Mednax's management efficiency ratios could be used to measure how well Mednax manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.07. In addition to that, Return On Capital Employed is expected to decline to 0. At present, Mednax's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 86.3 M, whereas Other Assets are forecasted to decline to about 212.4 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| John Rulli | Simon Property Group | 68 | |
| Anthony Puckett | Valvoline | 57 | |
| JAMAL MUASHSHER | Valvoline | 49 | |
| Patrick Guido | Asbury Automotive Group | 47 | |
| Tim Bozik | Pearson PLC ADR | 62 | |
| Frances Lockwood | Valvoline | 68 | |
| Richard Sokolov | Simon Property Group | 71 | |
| George Villasana | Asbury Automotive Group | 56 | |
| Julie ODaniel | Valvoline | 56 | |
| Julie Averill | Lululemon Athletica | 54 | |
| Thomas Gerrald | Valvoline | 56 | |
| Michael Welch | Asbury Automotive Group | 49 | |
| Heidi Matheys | Valvoline | 51 | |
| Brian McDade | Simon Property Group | 45 | |
| Rod Bristow | Pearson PLC ADR | 62 | |
| William Stax | Asbury Automotive Group | 48 | |
| Craig Moughler | Valvoline | 62 | |
| Michelle Choe | Lululemon Athletica | 55 | |
| Bob Whelan | Pearson PLC ADR | 71 | |
| Adam Reuille | Simon Property Group | 49 | |
| Robert Whelan | Pearson PLC ADR | 75 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | 0.0467 |
Mednax Inc Leadership Team
Elected by the shareholders, the Mednax's board of directors comprises two types of representatives: Mednax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mednax. The board's role is to monitor Mednax's management team and ensure that shareholders' interests are well served. Mednax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mednax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles CFA, Strategy Finance | ||
| Nanette Sanders, Senior Operations | ||
| Debra McRoberts, Senior Services | ||
| Enrique Sosa, Independent Director | ||
| Nikos Nikolopoulos, Executive Vice President Chief Strategy and Growth Officer | ||
| Michael Rucker, Independent Director | ||
| James MD, CEO Director | ||
| Paul Gabos, Independent Director | ||
| Pascal Goldschmidt, Independent Director | ||
| Roger Medel, Chief Executive Officer, Director | ||
| Cesar Alvarez, Independent Chairman of the Board | ||
| Dominic Andreano, Executive Vice President, General Counsel, Secretary | ||
| Mary Moore, Executive Vice President Chief Enterprise Risk and Legal Operations Officer | ||
| Mark Ordan, Chief Executive Officer, Director | ||
| Carlos Migoya, Independent Director | ||
| C Richards, Chief Financial Officer, Executive Vice President, Principal Accounting Officer | ||
| Kevin Pitzer, President Market | ||
| Linda Chen, President Operations | ||
| Stephen Farber, Chief Financial Officer, Executive Vice President | ||
| Michael MD, President Operations | ||
| John Pepia, Senior Vice President, Chief Accounting Officer | ||
| Jonathan Griffin, Integration Growth | ||
| John Starcher, Independent Director | ||
| Shirley Weis, Independent Director | ||
| Kasandra Rossi, Treasurer VP | ||
| CPC MBA, Senior Services | ||
| Waldemar Carlo, Independent Director | ||
| Mike Ashford, President Operations | ||
| Roger Hinson, President Pediatrix and Obstetrix Medical Group | ||
| Meghan Lublin, Chief VP | ||
| Manuel Kadre, Lead Independent Director | ||
| Michael Fernandez, Independent Director | ||
| Dana DreherRodwell, VP Officer | ||
| Suzanne Heck, President Market | ||
| Guy Sansone, Independent Chairman of the Board | ||
| Lee Wood, Executive Operations | ||
| Debra Kaspar, President Market | ||
| Roger MD, CoFounder Director | ||
| Cheryl VanPatten, Senior Officer | ||
| Karey Barker, Independent Director | ||
| Mary JD, Executive Officer | ||
| Marc Richards, Executive CFO | ||
| Thomas McEachin, Independent Director | ||
| Cheryl VanPattan, VP Officer | ||
| Curtis MD, Executive COO | ||
| Daniel Corcoran, Senior Care |
Mednax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mednax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | 0.0467 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 85.88 M | ||||
| Shares Owned By Insiders | 1.67 % | ||||
| Shares Owned By Institutions | 98.33 % | ||||
| Number Of Shares Shorted | 3.94 M | ||||
| Price To Earning | 89.39 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mednax. If investors know Mednax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mednax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.11) | Earnings Share (2.34) | Revenue Per Share 24.174 | Quarterly Revenue Growth 0.009 | Return On Assets 0.0467 |
The market value of Mednax Inc is measured differently than its book value, which is the value of Mednax that is recorded on the company's balance sheet. Investors also form their own opinion of Mednax's value that differs from its market value or its book value, called intrinsic value, which is Mednax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mednax's market value can be influenced by many factors that don't directly affect Mednax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mednax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mednax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mednax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.